GreenLight Announces Completion of Merger with Fall Line Endurance Fund LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the “NASDAQ”) before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each remaining share of GreenLight common stock not purchased in the Offer (other than shares of GreenLight common stock (i) owned by GreenLight as treasury stock, (ii) owned by Merger Sub immediately before the effective time of the Merger, (iii) that were irrevocably accepted by Merger Sub in the Offer, (iv) held by stockholders who have perfected their statutory rights of appraisal under Section 262 of the DGCL or (v) that are subject to the Contribution and Exchange Agreements entered into between Parent and certain stockholders of GreenLight) will be converted into the right to receive $0.30 in cash, without interest, and subject to deduction for any required withholding taxes.
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023 Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023
Why Greenlight Biosciences Stock Was in the Red Today The company reportedly turned down offers to go private.
GreenLight Biosciences to cut 25% of its workforce as part of ‘realignment' to extend cash runway GreenLight Biosciences Holdings GRNA, -1.44% said Wednesday that it was laying off 25% of its workforce as part of a “realignment” aimed at saving cash as it shifts its focus to near-term value drivers. The biotechnology company had 312 full-time employees as of March 31.
Why GreenLight Biosciences Stock Is Crushing It Today The momentum that began earlier this week for the biotech stock is accelerating.